Skip to main content
Clinical Trials/NCT02033928
NCT02033928
Completed
Not Applicable

Comprehensive Frailty Assessment

Ohio State University Comprehensive Cancer Center1 site in 1 country111 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myeloma, Multiple
Sponsor
Ohio State University Comprehensive Cancer Center
Enrollment
111
Locations
1
Primary Endpoint
Change in Comprehensive Frailty Assessment
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
August 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ashley Rosko

Principal Investigator

Ohio State University Comprehensive Cancer Center

Eligibility Criteria

Inclusion Criteria

  • patients with a plasma cell dyscrasia AND/OR any patient receiving a stem cell transplant for a hematologic malignancy at The Ohio State University
  • at least 18 years of age

Exclusion Criteria

  • Any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.

Outcomes

Primary Outcomes

Change in Comprehensive Frailty Assessment

Time Frame: up to 14 months

Responses to the Comprehensive Frailty Assessment will be assessed before and after treatment and changes will be evaluated. In transplant patients, this will be measured one year post transplant and in the non-transplant arm, this will be assessed after the second cycle of treatment.

Secondary Outcomes

  • Time to progression(date of enrollment to date of documented clinical progression up to two years post-enrollment)

Study Sites (1)

Loading locations...

Similar Trials